Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
April 12, 2026Cancer ReportsOpen Access

Complete Response to Nivolumab‐Relatlimab Following Progression of Invasive Sinonasal Mucosal Melanoma on First‐Line Nivolumab‐Ipilimumab: A Case Report

View Full Paper
Ask AI
Bookmark
Share

Authors

RPReema PatelLPLouisa Post‐ZwickerVKVarinder Kaur

Discussion

Loading...

Member takes

Overview

A case report finds complete response in sinonasal melanoma using nivolumab-relatlimab, suggesting a promising treatment option.

Key Points

  • The aim is to investigate the effectiveness of nivolumab-relatlimab in sinonasal mucosal melanoma progression following prior treatment.
  • Detailed patient case analysis of a 70-year-old male with sinonasal mucosal melanoma.
  • Initially treated with nivolumab-ipilimumab, followed by nivolumab-relatlimab after progression.
  • Monitored through PET-CT for disease stability and treatment responses.
  • Included radiation therapy to metastatic sites alongside immunotherapy.
  • Achieved complete response after 8 cycles of nivolumab-relatlimab.
  • Initial progression on nivolumab-ipilimumab deemed the tumor unresectable.
  • Patient's functional status deteriorated after treatment interruption, leading to supportive care.

Cite This Study

Patel et al. (2026) studied this question.

synapsesocial.com/papers/69db37df4fe01fead37c5f3bhttps://doi.org/10.1002/cnr2.70544
View Full Paper
Ask AI
Bookmark
Share